Adhesion Deregulation in Acute Myeloid Leukaemia

被引:27
作者
Gruszka, Alicja M. [1 ]
Valli, Debora [1 ]
Restelli, Cecilia [1 ]
Alcalay, Myriam [1 ,2 ]
机构
[1] Ist Europeo Oncol IRCCS, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Via Festa del Perdono 7, I-20122 Milan, Italy
关键词
acute myeloid leukaemia; adhesion molecules; EMT; EPITHELIAL-MESENCHYMAL TRANSITION; MEDIATED DRUG-RESISTANCE; BONE-MARROW NICHE; HYPOXIA-ACTIVATED PRODRUG; CXCR4 ANTAGONIST AMD3100; CHEMOKINE RECEPTOR CXCR4; INTEGRIN-LINKED KINASE; L-SELECTIN LIGAND; HEMATOPOIETIC STEM; CELL-ADHESION;
D O I
10.3390/cells8010066
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cell adhesion is a process through which cells interact with and attach to neighboring cells or matrix using specialized surface cell adhesion molecules (AMs). Adhesion plays an important role in normal haematopoiesis and in acute myeloid leukaemia (AML). AML blasts express many of the AMs identified on normal haematopoietic precursors. Differential expression of AMs between normal haematopoietic cells and leukaemic blasts has been documented to a variable extent, likely reflecting the heterogeneity of the disease. AMs govern a variety of processes within the bone marrow (BM), such as migration, homing, and quiescence. AML blasts home to the BM, as the AM-mediated interaction with the niche protects them from chemotherapeutic agents. On the contrary, they detach from the niches and move from the BM into the peripheral blood to colonize other sites, i.e., the spleen and liver, possibly in a process that is reminiscent of epithelial-to-mesenchymal-transition in metastatic solid cancers. The expression of AMs has a prognostic impact and there are ongoing efforts to therapeutically target adhesion in the fight against leukaemia.
引用
收藏
页数:20
相关论文
共 139 条
[1]   Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1 [J].
Abdelbaset-Ismail, A. ;
Borkowska-Rzeszotek, S. ;
Kubis, E. ;
Bujko, K. ;
Brzezniakiewicz-Janus, K. ;
Bolkun, L. ;
Kloczko, J. ;
Moniuszko, M. ;
Basak, G. W. ;
Wiktor-Jedrzejczak, W. ;
Ratajczak, M. Z. .
LEUKEMIA, 2017, 31 (02) :446-458
[2]   Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells [J].
Al-Souhibani, Norah ;
Al-Ghamdi, Maha ;
Al-Ahmadi, Wijdan ;
Khabar, Khalid S. A. .
CARCINOGENESIS, 2014, 35 (09) :1983-1992
[3]   Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing [J].
Alvarez, P. ;
Carrillo, E. ;
Velez, C. ;
Hita-Contreras, F. ;
Martinez-Amat, A. ;
Rodriguez-Serrano, F. ;
Boulaiz, H. ;
Ortiz, R. ;
Melguizo, C. ;
Prados, J. ;
Aranega, A. .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[4]   Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: First evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance. [J].
Andreeff, Michael ;
Konoplev, Sergej ;
Wang, Rui-Yu ;
Zeng, Zhihong ;
McQueen, Teresa ;
Shi, Yue-Xi ;
Medeiros, L. Jeffrey ;
Estey, Elihu ;
McCarty, John M. ;
Elkins, Stephanie ;
Champlin, Richard ;
Calandra, Gary ;
Bridger, Gary ;
Konopleva, Marina .
BLOOD, 2006, 108 (11) :171A-171A
[5]  
Andreeff M, 2012, BLOOD, V120
[6]  
[Anonymous], ROLE EMT MODULATORS
[7]  
[Anonymous], BLOOD
[8]  
[Anonymous], 2014, BLOOD, DOI DOI 10.1182/blood.V124.21.950.950
[9]  
[Anonymous], 2014, BLOOD
[10]   Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia [J].
Badar, Talha ;
Handisides, Damian R. ;
Benito, Juliana M. ;
Richie, Mary Ann ;
Borthakur, Gautam ;
Jabbour, Elias ;
Harutyunyan, Karine ;
Konoplev, Sergej ;
Faderl, Stefan ;
Kroll, Stew ;
Andreeff, Michael ;
Pearce, Tillman ;
Kantarjian, Hagop M. ;
Cortes, Jorge E. ;
Thomas, Deborah A. ;
Konopleva, Marina .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) :800-805